Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Celgene Corp., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net fixed asset turnover 12.00 11.68 11.39 11.17 11.20 10.91 10.83 12.12 12.45 12.29 12.15 12.03 12.06 11.82 11.43 11.25 12.36 12.32 12.18 11.77
Total asset turnover 0.41 0.42 0.42 0.43 0.43 0.42 0.39 0.43 0.39 0.40 0.40 0.40 0.40 0.38 0.37 0.34 0.32 0.47 0.45 0.44
Equity turnover 1.40 1.63 1.93 2.48 3.03 4.11 2.62 1.87 1.27 1.44 1.52 1.69 1.90 1.82 1.89 1.55 1.61 1.32 1.17 1.16

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Celgene Corp. net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Celgene Corp. total asset turnover ratio deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Celgene Corp. equity turnover ratio deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Net Fixed Asset Turnover

Celgene Corp., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 4,518 4,399 4,024 4,036 3,890 3,808 3,531 3,479 3,283 3,259 2,952 2,977 2,969 2,745 2,495 2,539 2,313 2,254 2,055 2,055 1,957 1,845 1,708
Property, plant and equipment, net 1,415 1,400 1,383 1,367 1,313 1,292 1,251 1,070 1,002 989 958 930 891 854 840 814 702 675 650 643 624 605 596
Long-term Activity Ratio
Net fixed asset turnover1 12.00 11.68 11.39 11.17 11.20 10.91 10.83 12.12 12.45 12.29 12.15 12.03 12.06 11.82 11.43 11.25 12.36 12.32 12.18 11.77
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Q3 2019 Calculation
Net fixed asset turnover = (Net product salesQ3 2019 + Net product salesQ2 2019 + Net product salesQ1 2019 + Net product salesQ4 2018) ÷ Property, plant and equipment, net
= (4,518 + 4,399 + 4,024 + 4,036) ÷ 1,415 = 12.00

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Celgene Corp. net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Total Asset Turnover

Celgene Corp., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 4,518 4,399 4,024 4,036 3,890 3,808 3,531 3,479 3,283 3,259 2,952 2,977 2,969 2,745 2,495 2,539 2,313 2,254 2,055 2,055 1,957 1,845 1,708
Total assets 41,363 39,183 37,639 35,480 34,215 33,444 34,556 30,141 31,736 30,306 28,820 28,086 26,754 26,562 25,964 27,053 27,369 17,746 17,481 17,340 16,403 15,602 12,705
Long-term Activity Ratio
Total asset turnover1 0.41 0.42 0.42 0.43 0.43 0.42 0.39 0.43 0.39 0.40 0.40 0.40 0.40 0.38 0.37 0.34 0.32 0.47 0.45 0.44
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Q3 2019 Calculation
Total asset turnover = (Net product salesQ3 2019 + Net product salesQ2 2019 + Net product salesQ1 2019 + Net product salesQ4 2018) ÷ Total assets
= (4,518 + 4,399 + 4,024 + 4,036) ÷ 41,363 = 0.41

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Celgene Corp. total asset turnover ratio deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Equity Turnover

Celgene Corp., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 4,518 4,399 4,024 4,036 3,890 3,808 3,531 3,479 3,283 3,259 2,952 2,977 2,969 2,745 2,495 2,539 2,313 2,254 2,055 2,055 1,957 1,845 1,708
Stockholders’ equity 12,087 10,051 8,165 6,161 4,860 3,430 5,172 6,921 9,850 8,445 7,644 6,599 5,650 5,549 5,075 5,919 5,376 6,322 6,765 6,525 5,768 4,851 4,485
Long-term Activity Ratio
Equity turnover1 1.40 1.63 1.93 2.48 3.03 4.11 2.62 1.87 1.27 1.44 1.52 1.69 1.90 1.82 1.89 1.55 1.61 1.32 1.17 1.16
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Q3 2019 Calculation
Equity turnover = (Net product salesQ3 2019 + Net product salesQ2 2019 + Net product salesQ1 2019 + Net product salesQ4 2018) ÷ Stockholders’ equity
= (4,518 + 4,399 + 4,024 + 4,036) ÷ 12,087 = 1.40

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Celgene Corp. equity turnover ratio deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.